Introduction {#section1-1533033819859413}
============

Renal cell carcinoma, one of the most malignant tumors, is associated with low survival rates because of resistance to conventional cancer therapies such as radiotherapy and chemotherapy as well as high degree of recurrence after curative surgeries because of distant metastases.^[@bibr1-1533033819859413],[@bibr2-1533033819859413]^ Therefore, there is urgent need for improved diagnostic and prognostic biomarkers that can accurately predict renal cell carcinoma progression. The etiology of renal cell carcinoma is not clear, and risk factors are not well established.

Many studies have shown that genetic polymorphisms in methylenetetrahydrofolate reductase (*MTHFR*), vitamin D receptor (*VDR*), and interleukin-16 (*IL-16*) are associated with the risk of renal cell carcinoma.^[@bibr3-1533033819859413][@bibr4-1533033819859413][@bibr5-1533033819859413][@bibr6-1533033819859413]-[@bibr7-1533033819859413]^ However, some of the findings are contradictory. Arjumand *et al* reported that *VDR* BsmI (rs1544410) was associated with pathogenesis of RCC.^[@bibr8-1533033819859413]^ But, Yang *et al* showed that there was no correlation between *VDR* BsmI genotypes and RCC.^[@bibr9-1533033819859413]^ The *MTHFR* rs1801133, *MTHFR* rs1801131, *VDR* ApaI (rs7975232), *VDR* BsmI (rs1544410), *VDR* TaqI (rs731236), *VDR* Fok1 (rs2228570), *IL-16* rs4778889, and *IL-16* rs11556218 are polymorphisms associated with risk of prostate, lung, breast, and ovarian cancer.^[@bibr10-1533033819859413][@bibr11-1533033819859413][@bibr12-1533033819859413][@bibr13-1533033819859413][@bibr14-1533033819859413][@bibr15-1533033819859413][@bibr16-1533033819859413][@bibr17-1533033819859413]-[@bibr18-1533033819859413]^

Many studies have identified *MTHFR*, *VDR*, and *IL-16* gene polymorphisms in renal cell carcinoma. Therefore, we conducted a comprehensive meta-analysis to investigate whether the polymorphisms in the *MTHFR*, *VDR*, and *IL-16* genes are associated with the risk of renal cell carcinoma.

Materials and Methods {#section2-1533033819859413}
=====================

Literature Search Strategy {#section3-1533033819859413}
--------------------------

We identified 73 articles after searching the PubMed, and Cochrane Library databases until July 1, 2017, with the following keywords: *methylenetetrahydrofolate reductase* OR *MTHFR* OR *vitamin D receptor* OR *VDR* OR *interleukin-16* OR *IL-16* and *renal cell carcinoma* OR *renal cell cancer*. Among these, we searched case--control studies that reported renal cell cancer outcomes and provided data regarding *MTHFR*, *VDR*, and *IL-16* genotype distribution for inclusion in our meta-analysis. We excluded articles that were (1) reviews and editorials, (2) case reports, (3) did not report *MTHFR*, *VDR*, and *IL-16* gene polymorphism or renal cell cancer outcomes, and (4) did not investigate the role of *MTHFR*, *VDR*, and *IL-16* gene expression to renal cell cancer. If multiple publications were identified for the same data, we only recruited the latest paper for our final analysis.

Data Extraction {#section4-1533033819859413}
---------------

The following information was extracted from each eligible study by 2 independent investigators: first author's surname, publication year, location of the study conducted, ethnicity, control source of the control group, and the number of cases and controls for *MTHFR*, *VDR*, and *IL-16* genotypes. Any disagreements in the 2 sets of data were resolved by discussion.

Statistical Analysis {#section5-1533033819859413}
--------------------

Statistical analyses were performed with the Cochrane Review Manager Version 5 (Cochrane Library, London, United Kingdom). In most cases, the pooled statistics were analyzed by the fixed effects model (Mantel-Haenszel method), but random effects model (DerSimonian-Laird method) was used to analyze data when *P* ~heterogeneity~ \< .1. Data were expressed as odds ratios (ORs) and 95% confidence intervals (CIs) for dichotomous data. *P* \< .05 was considered statistically significant for pooled ORs. *I* ^2^ was used to test the heterogeneity among the included studies. We conducted subgroup analysis when more than 2 included reports were available for analysis.

Results {#section6-1533033819859413}
=======

Study Characteristics {#section7-1533033819859413}
---------------------

The literature search yielded 73 studies with 72 from PubMed and 1 from Cochrane Library ([Figure 1](#fig1-1533033819859413){ref-type="fig"}). Based on inclusion and exclusion criteria, 12 articles were identified for this meta-analysis. As shown in [Table 1](#table1-1533033819859413){ref-type="table"}, 3 included studies reported the relationship between *MTHFR* gene polymorphism and renal cell carcinoma susceptibility.^[@bibr3-1533033819859413],[@bibr19-1533033819859413],[@bibr20-1533033819859413]^ All 3 studies analyzed *MTHFR* 677C/T rs1801133,^[@bibr3-1533033819859413],[@bibr19-1533033819859413],[@bibr20-1533033819859413]^ whereas 2 studies assessed *MTHFR* 1298A/C rs1801131.^[@bibr3-1533033819859413],[@bibr19-1533033819859413]^

![Flow chart of study search and selection.](10.1177_1533033819859413-fig1){#fig1-1533033819859413}

###### 

Effects of MTHFR Gene Polymorphism on Renal Cell Carcinoma Risk.

![](10.1177_1533033819859413-table1)

  Gene Sites   Author, Year          Ethnicity   Country/Subgroup   Source of Control   Case   Control                                   
  ------------ --------------------- ----------- ------------------ ------------------- ------ --------- ----- ------- ----- ----- ----- -------
  rs1801133    Moore *et al*, 2008   Caucasian   Europe             Hospital            93     370       355   818     113   419   556   1088
               Ajaz *et al*, 2012    Asian       Pakistan           Population          4      50        108   162     6     50    121   177
               Lv *et al*, 2015      Asian       China              Population          16     32        33    81      23    36    21    80
  rs1801131                                                                             CC     AC        AA    Total   CC    AC    AA    Total
               Moore *et al*, 2008   Caucasian   Europe             Hospital            85     357       376   818     113   483   491   1087
               Ajaz *et al*, 2012    Asian       Pakistan           Population          19     106       43    168     8     105   59    172

Abbreviation: MTHFR, methylenetetrahydrofolate reductase.

As shown in [Table 2](#table2-1533033819859413){ref-type="table"}, 6 studies reported the relationship between *VDR* gene polymorphism and the susceptibility of renal cell carcinoma.^[@bibr4-1533033819859413],[@bibr5-1533033819859413],[@bibr8-1533033819859413],[@bibr9-1533033819859413],[@bibr21-1533033819859413],[@bibr22-1533033819859413]^ Among these, 2 studies analyzed *VDR* ApaI rs7975232,^[@bibr9-1533033819859413],[@bibr21-1533033819859413]^ whereas 4 studies each reported *VDR* BsmI rs1544410,^[@bibr5-1533033819859413],[@bibr8-1533033819859413],[@bibr9-1533033819859413],[@bibr21-1533033819859413]^ *VDR* TaqI rs731236,^[@bibr4-1533033819859413],[@bibr5-1533033819859413],[@bibr9-1533033819859413],[@bibr21-1533033819859413]^ and *VDR* Fok1 rs2228570^[@bibr5-1533033819859413],[@bibr8-1533033819859413],[@bibr9-1533033819859413],[@bibr22-1533033819859413]^ gene polymorphisms.

###### 

Summary of the Effects of VDR Gene Polymorphism on Renal Cell Carcinoma Risk.

![](10.1177_1533033819859413-table2)

  Restriction Sites   Author, Year             Ethnicity       Country/Subgroup   Source of Control   Case   Control                                   
  ------------------- ------------------------ --------------- ------------------ ------------------- ------ --------- ----- ------- ----- ----- ----- -------
  ApaI                Obara *et al*, 2007      Asian           Japan              Population          23     52        60    135     11    71    68    150
                      Yang *et al*, 2016       Asian           China              Population          35     153       114   302     18    135   149   302
  BsmI                                                                                                BB     Bb        bb    Total   BB    Bb    bb    Total
                      Obara *et al*, 2007      Asian           Japan              Population          0      33        102   135     1     41    108   150
                      Karami *et al*, 2008     Caucasian       United States      Hospital            81     370       324   775     112   474   407   993
                      Arjumand *et al*, 2012   Asian           Indian             Healthy             50     88        58    196     83    130   37    250
                      Yang *et al*, 2016       Asian           China              Population                           255   302                 265   302
  TaqI                                                                                                tt     Tt        TT    Total   tt    Tt    TT    Total
                      Ikuyama *et al*, 2002    Asian           Japan              Hospital            1      19        82    102     8     70    126   204
                      Obara *et al*, 2007      Asian           Japan              Population          0      31        104   135     1     37    112   150
                      Karami *et al*, 2008     United States   Caucasian          Hospital            97     361       320   778     137   438   402   977
                      Yang *et al*, 2016       Asian           China              Population                           261   302                 272   302
  Fok1                                                                                                ff     Ff        FF    Total   ff    Ff    FF    Total
                      Karami *et al*, 2008     Caucasian       United States      Hospital            149    376       286   811     199   492   338   1029
                      Arjumand *et al*, 2012   Asian           Indian             Healthy             40     94        62    196     38    98    114   250
                      Southard *et al*, 2012   Caucasian       Finland            Healthy             22     66        64    152     48    144   113   305
                      Yang *et al*, 2016       Asian           China              Population          61     171       70    302     64    159   79    302

Abbreviation: VDR, vitamin D receptor.

As shown in [Table 3](#table3-1533033819859413){ref-type="table"}, 3 studies reported the relationship between *IL-16* gene polymorphism and renal cell carcinoma susceptibility in Chinese population.^[@bibr6-1533033819859413],[@bibr7-1533033819859413],[@bibr23-1533033819859413]^ Among these, 3 studies reported *IL-16* rs4778889,^[@bibr6-1533033819859413],[@bibr7-1533033819859413],[@bibr23-1533033819859413]^ whereas 2 studies reported *IL-16* rs11556218^[@bibr6-1533033819859413],[@bibr23-1533033819859413]^ gene polymorphisms.

###### 

Effects of IL-16 Gene Polymorphism on Renal Cell Carcinoma Risk.

![](10.1177_1533033819859413-table3)

  Restriction Sites   Author, Year         Country/Subgroup   Source of Control   Case   Control                                  
  ------------------- -------------------- ------------------ ------------------- ------ --------- ----- ------- ---- ----- ----- -------
  rs4778889           Zhu *et al*, 2010    China              Hospital            14     122       199   335     34   135   171   340
                      Wang *et al*, 2015   China              Hospital            22     77        82    181     12   106   160   278
                      Yang *et al*, 2016   China              Hospital            28     113       132   273     14   84    176   274
  rs11556218                                                                      GG     TG        TT    Total   GG   TG    TT    Total
                      Wang *et al*, 2015   China              Population          12     75        94    181     15   108   155   278
                      Yang *et al*, 2016   China              Hospital            15     110       149   274     12   107   155   274

Abbreviation: IL-16, interleukin-16.

Association of *MTHFR* Gene Polymorphism With Renal Cell Carcinoma Susceptibility {#section8-1533033819859413}
---------------------------------------------------------------------------------

The *MTHFR* rs1801133 (T allele as well as TT and CC genotypes) and rs1801131 (C allele as well as CC and AA genotypes) were not associated with renal cell carcinoma risk ([Figure 2](#fig2-1533033819859413){ref-type="fig"} and [Table 4](#table4-1533033819859413){ref-type="table"}).

![Association of methylenetetrahydrofolate reductase (MTHFR) rs1801133 gene polymorphism with renal cell carcinoma susceptibility.](10.1177_1533033819859413-fig2){#fig2-1533033819859413}

###### 

Association of MTHFR, VDR, and IL-16 Gene Polymorphisms With Renal Cell Carcinoma Risk.^a^

![](10.1177_1533033819859413-table4)

  Alleles and Genotypes   Group and Subgroups   Studies Number   Q Test *P* Value   Model Selected   OR (95% CI)        *P*
  ----------------------- --------------------- ---------------- ------------------ ---------------- ------------------ -----------
  MTHFR rs1801133                                                                                                       
  T vs C                  Overall               3                .01                Random           0.96 (0.66-1.41)   .84
                          Asian                 2                .10                Fixed            0.82 (0.61-1.10)   .19
  TT vs (CT + CC)         Overall               3                .29                Fixed            1.00 (0.77-1.31)   .98
                          Asian                 2                .82                Fixed            0.64 (0.34-1.20)   .16
  CC vs (CT + TT)         Overall               3                .02                Random           1.00 (0.62-1.61)   1.00
                          Asian                 2                .07                Random           1.28 (0.63-2.62)   .50
  MTHFR rs1801131                                                                                                       
  C vs A                  Overall               2                .05                Random           1.13 (0.81-1.57)   .46
  CC vs (AC + AA)         Overall               2                .29                Fixed            1.48 (0.59-3.74)   .41
  AA vs (AC + CC)         Overall               2                .08                Random           0.87 (0.57-1.33)   .52
  VDR ApaI                                                                                                              
  A vs a                  Asian                 2                .47                Fixed            1.41 (1.15-1.72)   **.0007**
  AA vs Aa + aa           Asian                 2                .64                Fixed            2.25 (1.41-3.60)   **.0007**
  aa vs AA + Aa           Asian                 2                .13                Fixed            0.72 (0.55-0.94)   **.01**
  VDR BsmI                                                                                                              
  B vs b                  Overall               3                .02                Random           0.81 (0.60-1.09)   .17
                          Asian                 2                .34                Fixed            0.68 (0.54-0.85)   **.001**
  BB vs Bb + bb           Overall               3                .49                Fixed            0.83 (0.65-1.05)   .12
                          Asian                 2                .70                Fixed            0.68 (0.45-1.03)   .07
  bb vs Bb + BB           Overall               4                .003               Random           1.21 (0.79-1.85)   .37
                          Asian                 3                .0005              Random           1.35 (0.43-4.22)   .60
  VDR TaqI                                                                                                              
  t vs T                  Overall               3                .01                Random           0.74 (0.46-1.19)   .21
                          Asian                 2                .05                Random           0.61 (0.31-1.22)   .16
  tt vs Tt + TT           Overall               3                .43                Fixed            0.84 (0.64-1.10)   .20
                          Asian                 2                .83                Fixed            0.27 (0.05-1.55)   .14
  TT vs Tt + tt           Overall               4                .007               Random           1.16 (0.75-1.78)   .50
                          Asian                 3                .004               Random           1.25 (0.60-2.61)   .54
  VDR Fok1                                                                                                              
  f vs F                  Overall               4                .01                Random           1.05 (0.85-1.29)   .64
                          Asian                 2                .04                Random           1.24 (0.87-1.76)   .24
                          Caucasian             2                .68                Fixed            0.92 (0.82-1.04)   .19
  ff vs Ff + FF           Overall               4                .47                Fixed            0.99 (0.83-1.18)   .90
                          Asian                 2                .19                Fixed            1.11 (0.82-1.51)   .51
                          Caucasian             2                .91                Fixed            0.93 (0.75-1.16)   .53
  FF vs Ff + ff           Overall               4                .008               Random           0.91 (0.66-1.26)   .57
                          Asian                 2                .11                Fixed            0.69 (0.53-0.91)   **.007**
                          Caucasian             2                .64                Fixed            1.14 (0.95-1.35)   .15
  IL-16 rs4778889                                                                                                       
  C vs T                  Asian                 3                \<.00001           Random           1.24 (0.66-2.33)   .50
  CC vs CT + TT           Asian                 3                \<.0001            Random           1.36 (0.38-4.79)   .64
  TT vs CT + CC           Asian                 3                \<.0001            Random           0.78 (0.40-1.50)   .45
  IL-16 rs11556218                                                                                                      
  G vs T                  Asian                 2                .84                Fixed            1.11 (0.91-1.36)   .30
  GG vs TG + TT           Asian                 2                .98                Fixed            1.25 (0.72-2.18)   .42
  TT vs TG + GG           Asian                 2                .80                Fixed            0.89 (0.69-1.14)   .36

Abbreviations: CI, confidence interval; IL-16, interleukin-16; MTHFR, methylenetetrahydrofolate reductase; OR, odds ratio; VDR, vitamin D receptor.

^a^Bold values were significant.

Association Between *VDR* Gene Polymorphism and Renal Cell Carcinoma Susceptibility {#section9-1533033819859413}
-----------------------------------------------------------------------------------

The *VDR* ApaI A allele as well as AA and aa genotypes were associated with renal cell carcinoma risk in Asians (A allele: OR = 1.41, 95% CI: 1.15-1.72, *P* = .0007; AA genotype: OR = 2.25, 95% CI: 1.41-3.60, *P* = .0007; aa genotype: OR = 0.72, 95% CI: 0.55-0.94, *P* = .01; [Table 4](#table4-1533033819859413){ref-type="table"}). The *VDR* BsmI alleles and genotypes were not associated with the risk of renal cell carcinoma (B allele: OR = 0.81, 95% CI: 0.60-1.09, *P* = .17; BB genotype: OR = 0.83, 95% CI: 0.65-1.05, *P* = .12; bb genotype: OR = 1.21, 95% CI: 0.79-1.85, *P* = .37; [Table 4](#table4-1533033819859413){ref-type="table"}). In Asian population, B allele was associated with the risk of renal cell carcinoma, but BB genotype and bb genotype were not (B allele: OR = 0.68, 95% CI: 0.54-0.85, *P* = .001; BB genotype: OR = 0.68, 95% CI: 0.45-1.03, *P* = .07; bb genotype: OR = 1.35, 95% CI: 0.43-4.22, *P* = .60; [Table 4](#table4-1533033819859413){ref-type="table"}).

The *VDR* TaqI allele and genotypes were not associated with the risk of renal cell carcinoma (t allele: OR = 0.74, 95% CI: 0.46-1.19, *P* = .21; tt genotype: OR = 0.84, 95% CI: 0.64-1.10, *P* = .20; TT genotype: OR = 1.16, 95% CI: 0.75-1.78, *P* = .50; [Table 4](#table4-1533033819859413){ref-type="table"}).

The *VDR* Fok1 allele and genotype were not associated with the risk of renal cell carcinoma (f allele: OR = 1.05, 95% CI: 0.85-1.29, *P* = .64; ff genotype: OR = 0.99, 95% CI: 0.83-1.18, *P* = .90; FF genotype: OR = 0.91, 95% CI: 0.66-1.26, *P* = .57; [Figure 3](#fig3-1533033819859413){ref-type="fig"} and [Table 4](#table4-1533033819859413){ref-type="table"}). In Asian population, FF genotype was associated with the risk of renal cell carcinoma ([Table 4](#table4-1533033819859413){ref-type="table"}), but F allele and ff genotype were not. Furthermore, *VDR* BsmI f allele as well as ff and FF genotypes were not associated with the risk of renal cell carcinoma in Caucasians ([Table 4](#table4-1533033819859413){ref-type="table"}).

![Association of vitamin D receptor (VDR) Fok1 gene polymorphism with renal cell carcinoma susceptibility.](10.1177_1533033819859413-fig3){#fig3-1533033819859413}

Association of *IL-16* Gene Polymorphism With the Susceptibility of Renal Cell Carcinoma {#section10-1533033819859413}
----------------------------------------------------------------------------------------

The *IL-16* rs4778889 C allele and genotype were not associated with the risk of renal cell carcinoma in Chinese population (C allele: OR = 1.24, 95% CI: 0.66-2.33, *P* = .50; CC genotype: OR = 1.36, 95% CI: 0.38-4.79, *P* = .64; TT genotype: OR = 0.78, 95% CI: 0.40-1.50, *P* = .45; [Figure 4](#fig4-1533033819859413){ref-type="fig"}; [Table 4](#table4-1533033819859413){ref-type="table"}). Moreover, the *IL-16* rs11556218 G allele, GG and TT genotypes were also not associated with renal cell carcinoma risk in Chinese population (G allele: OR = 1.11, 95% CI: 0.91-1.36, *P* = .30; GG genotype: OR = 1.25, 95% CI: 0.72-2.18, *P* = .42; TT genotype: OR = 0.89, 95% CI: 0.69-1.14, *P* = .36; [Table 4](#table4-1533033819859413){ref-type="table"}).

![Association of interleukin-16 (IL-16) rs4778889 gene polymorphism with renal cell carcinoma susceptibility.](10.1177_1533033819859413-fig4){#fig4-1533033819859413}

Discussion {#section11-1533033819859413}
==========

In previous studies, the gene polymorphisms have been associated with increased susceptibility of renal cell carcinoma. Our study indicated that *MTHFR* rs1801133 (T allele, TT and CC genotypes) as well as *MTHFR* rs1801131 (C allele, CC and AA genotypes) were not associated with renal cell carcinoma risk ([Table 4](#table4-1533033819859413){ref-type="table"}). Since the number of included studies were small, further investigations are necessary to confirm these findings. The MTHFR, a central enzyme involved in folate metabolism, plays an important role in DNA synthesis and methylation that are relevant in cancer pathogenesis.^[@bibr24-1533033819859413][@bibr25-1533033819859413]-[@bibr26-1533033819859413]^ Our findings suggest that *MTHFR* rs1801133 and rs1801131 gene polymorphisms do not affect DNA synthesis and methylation, and therefore, do not influence the onset of renal cell carcinoma.

The *VDR* BsmI, TaqI, and Fok1 gene polymorphisms are not associated with renal cell carcinoma risk in overall populations. Interestingly, *VDR* ApaI (A allele, AA and aa genotypes, BsmI B allele, and Fok1 FF genotype are associated with the risk of renal cell carcinoma. Ou *et al* conducted a meta-analysis and demonstrated that the ApaI AA genotype, BsmI BB genotype, Fok1 f allele, and Fok1 FF genotype were associated with renal cell carcinoma risk in Asians.^[@bibr27-1533033819859413]^ Our study was more robust as it included more studies than Ou *et al.* ^[@bibr27-1533033819859413]^ Vitamin D regulates the cell proliferation, differentiation, and apoptosis in various tissues and plays a protective role in some cancer types.^[@bibr28-1533033819859413],[@bibr29-1533033819859413]^ We showed that *VDR* ApaI (A allele, AA genotype, aa genotype), BsmI B allele, *and* Fok1 FF genotype are associated with onset of renal cell carcinoma suggesting that these polymorphisms alter the activity of VDR.

Our meta-analysis also showed that *IL-16* rs4778889 (C allele, CC and TT genotypes) as well as rs11556218 (G allele, GG and TT genotypes) gene polymorphisms were not associated with renal cell carcinoma risk in Chinese population. Interleukin-16 is a multifunctional pro-inflammatory cytokine, which is associated with many complex human disorders as it plays a critical role in regulating cellular homoeostasis.^[@bibr30-1533033819859413]^ Our study demonstrates that IL-16 rs4778889 and rs11556218 gene polymorphisms did not alter IL-16 function and therefore was not involved in the onset of renal cell carcinoma.

Our study demonstrates that the *VDR* ApaI (A allele, AA and aa genotypes), BsmI B allele, and Fok1 FF genotype are potential indicators of renal cell carcinoma risk in Asians. This needs to be confirmed by large-scale studies in future. Furthermore, the association of haplotype blocks of those genes with renal cell carcinoma needs to be investigated.

Gene disfunction could induce the disorders of cell growth and differentiation, and it can lead to the out of control of cell proliferation and apoptosis which affects the susceptibility of RCC. The MTHFR, a critical enzyme in the metabolism of folic acid, converts 5, 10-methylenetetrahydrofolate acid into 5-methyltetrahydrofolate and is a key importance for the homocysteine metabolism.^[@bibr31-1533033819859413],[@bibr32-1533033819859413]^ The active form of vitamin D acts as a steroid hormone and binds to the VDR. Vitamin D receptor mediates many genomic and nongenomic effects of vitamin D.^[@bibr33-1533033819859413]^ This receptor is expressed in most cell types including cells in kidney. Interleukin-16, a multifunctional pro-inflammatory cytokine, plays a critical role in regulation of cellular functions such as homoeostasis and affects the secretion of tumor-related inflammatory cytokines.^[@bibr30-1533033819859413],[@bibr34-1533033819859413]^ The current evidences indicated that MTHFR, VDR, and IL-16 take part in the pathogenesis of cancers.

The limitations of our study include small sample size, limited statistical power, heterogeneity of enrolled cases, variable study designs, and various interventions. These may have affected the statistical results and hence need to be regarded cautiously and confirmed in the future.

In conclusion, we demonstrate the association of *VDR* ApaI A allele, AA genotype, aa genotype, BsmI B allele, and Fok1 FF genotype are associated with the risk of renal cell carcinoma in Asians.
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